Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from PureTech Health ( (GB:PRTC) ) is now available.
PureTech Health has reported its share capital and voting rights position as of 31 March 2026, confirming an issued share capital of 257,927,489 ordinary shares, of which 14,509,299 are held in treasury. This leaves a total of 243,418,190 voting rights in the company, a key reference figure for investors assessing whether they must disclose holdings or changes under U.K. transparency rules.
The disclosure ensures compliance with regulatory reporting requirements and supports market transparency around PureTech Health’s ownership structure. Shareholders and potential investors can use these figures to monitor their thresholds for mandatory notifications, which is particularly relevant for institutional holders tracking governance influence and regulatory obligations.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £139.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on PRTC Stock
According to Spark, TipRanks’ AI Analyst, PRTC is a Neutral.
PureTech Health’s overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company’s strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.
To see Spark’s full report on PRTC stock, click here.
More about PureTech Health
PureTech Health is a biotherapeutics company operating a hub-and-spoke R&D model focused on developing therapeutics with validated pharmacology to address significant unmet patient needs. Its capital-efficient strategy has generated dozens of therapeutic candidates, including three drugs that have received U.S. FDA approval, and emphasizes scaling high-conviction assets with external funding to create long-term shareholder value.
Average Trading Volume: 436,986
Technical Sentiment Signal: Strong Sell
Current Market Cap: £262.5M
For an in-depth examination of PRTC stock, go to TipRanks’ Overview page.